Market Movers (8-K)
OID
BioStem Technologies has entered into a $40 million Committed Equity Facility with Roth Principal Investments, providing flexible access to capital for working capital and general corporate purposes.
Capital raise
OID
BioStem Technologies announced strong sequential revenue growth of 29% to $7.9 million for Q2 2026, raised full-year guidance, and successfully uplisted to the Nasdaq Capital Market.
Capital raise
Quarterly Earnings (10-Q)
OID
BioStem Technologies' Q2 2026 Form 10-Q reveals a significant revenue decrease and increased operating costs, leading to a substantial net loss, though offset by a strategic acquisition and ongoing financing efforts.
Delay expected
Capital raise
Worse than expected
Insider Trading (Form 4)
See all →OID
Vurst Andrew Smith-Van, Chief Operating Officer, a Director and 10% owner of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Jason Matuszewski, Chief Executive Officer, a Director and 10% owner of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Kenneth Howard Warrington Jr, a Director of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Michael A Fortunato, Chief Accounting Officer of Biostem Technologies, reported multiple transactions in common stock on September 15, 2026.
OID
Barry Hassett, Chief Commercial Officer of Biostem Technologies, reported multiple transactions in common stock on September 9, 2026.
OID
Jodi Ungrodt, a Director of Biostem Technologies, reported multiple transactions in common stock on August 27, 2026.
New Public Companies (S-1)
OID
BioStem Technologies files for a $40 million at-the-market equity offering with Roth Principal Investments, highlighting significant dilution risks and ongoing going concern uncertainties.
Capital raise
Worse than expected
OID
BioStem Technologies files an S-1/A amendment detailing a significant revenue decrease in Q1 2026 compared to the prior year, alongside a net loss, while also outlining strategic acquisitions and future growth plans.
Worse than expected
Capital raise
OID
BioStem Technologies, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 3,571,429 shares of common stock.
Worse than expected
Capital raise